BridgeMD
New treatment option for Acute Myeloid Leukemia
Official title Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
ClinicalTrials.gov ID: NCT06328179
What this study is testing
What is Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；?
Venetoclax 100 mg d1，200 mg d2，400 mg d3-14； is an investigational medicine, being studied as a potential treatment for acute myeloid leukemia.
Also referred to as Homoharringtoine, HHT 2 mg/m2，qd，d1-7, Etoposide 0.1 g，qd，d1-5.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities. This study includes the induction and consolidation phases of AML treatment.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Age between 18 and 60 years old;Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Expected survival time of at least 3 months.
- Does not meet any of the following criteria for severe heart, lung, liver, or kidney disease:A) History of congestive heart failure requiring...
- No other significant contraindications to chemotherapy as determined by the physician;
- Capable of understanding and willing to sign the informed consent form for this study.
You likely can't join if
- Presence of other malignancies;
- Underwent cardiac vascular intervention or stent placement within 12 months prior to signing the informed consent, or history of myocardial...
- Uncontrolled active infection (including bacterial, fungal, or viral infection) and visceral bleeding;
- Pregnant or lactating women;
- Participation in any other clinical study within 3 months prior to signing the informed consent;
- Any other condition deemed unsuitable for participation in this study by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Huai'an, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Huai'an, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.